Bimzelx – Talk Bio

Actionable Insights Powered by AI

UCB’s Bimzelx Receives FDA Approval for Moderate-to-Severe Hidradenitis Suppurativa, Marking Fifth Indication

5 months ago talkbio0Tagged Approved, bimekizumab, Bimzelx, Chronic Inflammatory Skin Disease, Hidradenitis, IL-17F inhibitor, IL17A protein, human, suppurativa, United States Food and Drug Administration

Bimzelx, Bimekizumab, Hidradenitis Suppurativa, FDA Approval, IL-17A and IL-17F Inhibitor, Chronic Inflammatory Skin Disease

UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases

7 months ago talkbio0Tagged Ankylosing spondylitis, approvals, Arthritis, Psoriatic, Bimzelx, IL17A protein, human, IL17F gene, Inhibitor, non-radiographic axial, Spondylarthritis, UCB, United States Food and Drug Administration

Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor

FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

7 months ago talkbio0Tagged Ankylosing spondylitis, Approved, Arthritis, Psoriatic, Bimzelx, IL-17F inhibitor, IL17A protein, human, non-radiographic axial, Spondylarthritis, United States Food and Drug Administration

Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor